Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial

NCT ID: NCT01704950

Last Updated: 2016-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to provide data and the guidelines for the use of IDRT SL in small wounds, acute and chronic (less than 6 months), showing the benefits and the easy to use of this product as a one stage procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Wound Reconstruction Wound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patient with 1 traumatic wound (burns included) or 1 reconstruction wound (oncological wounds included)
* Patients for whom the surgeon has recommended that an INTEGRA® SL matrix be implanted (even if the patient is not taking part in the study) with a Split Thickness Skin Graft in the same operating procedure
* Wound treated with only one layer of a maximum size 10cm\*12.5cm

Exclusion Criteria

* Immunosuppressed patient
* Chronic wound (with no healing since 6 months)
* Addition of any substances (growth factor, stem cells,…) in the IDRT SL during the surgery
* Patient with a corticoid treatment with a daily dose greater than 5 mg
* Patients whose life expectancy is less than 12 months
* Patients whose mental health or health condition (Visual deficiency, Alzheimers…) would compromise completion of the self-evaluation questionnaires
* Patient with an hypersensitivity to bovine collagen, chondroitin
* Patient with clinical signs of infection (fever, pain, colour, swelling,…) and for whom the investigator diagnosed infection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Integra LifeSciences Services

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefanos Papadopoulos

Role: PRINCIPAL_INVESTIGATOR

General State Hospital of Athens, "G. Gennimatas"

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Josef Hospital

Bochum, , Germany

Site Status

General State Hospital of Athens, "G. Gennimatas" - Department of Plastic Surgery-Microsurgery and Burn Center

Athens, , Greece

Site Status

University Hospital "S. Maria della Misericordia" - Plastic Surgery and Burn Center

Udine, , Italy

Site Status

Queen Elizabeth Hospital - Burn and Plastic Surgery

Birmingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Greece Italy United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RECON-EMEA-11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.